Adalimumab

© GettyImages/image_jungle

Celltrion secures EU approval for its adalimumab biosimilar

By Jane Byrne

Celltrion’s adalimumab biosimilar, Yuflyma (CT-P17) has been approved by the European Commission for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers